545 upcoming catalysts — clinical readouts, PDUFA dates, FDA decisions, and conference data cuts — ranked by importance and searchable by company, asset, or therapeutic area. 8 verified · 537 live-sourced.
545 catalysts · showing first 25
VKTX·VK2735 (oral)
Market Moving
Clinical ReadoutMetabolicPhase 3
Obesity
ExpectedQ3 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
65%
Why It Matters
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
REGN·Dupixent (IL-4Rα)
Market Moving
FDA DecisionRespiratoryRegistration
COPD
ExpectedQ3 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
80%
Why It Matters
First biologic approved for COPD would open a massive new market. Commercial peak sales estimates of $3B+ annually. Eosinophilic COPD subgroup most likely to benefit.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
LLY·Tirzepatide
Important
Clinical ReadoutCardiovascularPhase 3
Heart Failure with Preserved EF
ExpectedH2 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
60%
Why It Matters
HFpEF has no approved pharmacological treatments. Positive data would expand GLP-1 addressable market substantially and reinforce cardiovascular benefits beyond weight loss.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
·ALECENSA - alectinib hydrochloride capsule
Important
Clinical ReadoutOncologyPhase 2/Phase 3
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Abiraterone - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Prostate Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·ETOPOSIDE - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Selinexor (combination therapy)
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Relapsed/Refractory Diffuse Large B-cell Lymphoma
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·BHV-7000
Important
Clinical ReadoutCNSPhase 2/Phase 3
Focal Epilepsy
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Raloxifene - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Breast Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Treprostinil Palmitil
Important
Clinical ReadoutCardiovascularPhase 2/Phase 3
Pulmonary Arterial Hypertension
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
56%
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·LM-302
Important
Clinical ReadoutOncologyPhase 3
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Pembrolizumab
Important
Clinical ReadoutOncologyPhase 3
Endometrial Neoplasms
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Avelumab
Important
Clinical ReadoutOncologyPhase 3
Solid Tumors
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Avelumab Program Rollover Study
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Dostarlimab
Important
Clinical ReadoutOncologyPhase 3
Neoplasms
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·A166
Important
Clinical ReadoutOncologyPhase 3
HER2-positive Breast Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Atezolizumab
Important
Clinical ReadoutOncologyPhase 3
Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·AK105 Injection
Important
Clinical ReadoutOncologyPhase 3
Advanced Hepatocellular Carcinoma (HCC)
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·BL-B01D1
Important
Clinical ReadoutOncologyPhase 3
Small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Apalutamide
Important
Clinical ReadoutOncologyPhase 3
Prostatic Neoplasms
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·1.0mg/kg/day PRAX-562
Important
Clinical ReadoutCNSPhase 3
Developmental and Epileptic Encephalopathy 1
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·SKB264
Important
Clinical ReadoutOncologyPhase 3
Non-Small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·BL-B01D1
Important
Clinical ReadoutOncologyPhase 3
Non-small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·TQB3454 tablets
Important
Clinical ReadoutOncologyPhase 3
Biliary Carcinoma
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·SHR-A2009 monotherapy
Important
Clinical ReadoutOncologyPhase 3
Non-small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·RYZ101
Important
Clinical ReadoutOncologyPhase 3
GEP-NET
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
Verified: Editor-reviewed catalyst with validated timing, source context, and executive summary.
Live-Sourced: Pulled from public data sources and refreshed periodically. Timing and details should be independently verified.
PoS estimates are illustrative figures based on BIO/IQVIA phase benchmarks — not primary research. Click any catalyst to view full program details.